Clinical trial for assessing if gentic information obtained with NEUROFARMAGEN test is effective for selecting the treatment in patients with mental disorders

• Conditions: Major depressive disorderschizophreniaBipolar disorderobsessive-compulsive disorder; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2013-002228-18-ES
• Lead Sponsor: AB-BIOTICS S.A.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09-16
• Last Update Posted: 18 January 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-Patients of either sex over 18 years.
-Patients with any of the following psychiatric diagnoses according to DSM-IV-TR: bipolar disorder, schizophrenia, major depressive disorder or obsessive-compulsive disorder
-Patients who have given their written informed consent to participate in the study. In the case of disabled patients, informed consent of the legal representative or family member.
-Patients with a value on the clinical global impression scale of severity (CGI-S) according to the doctor less than 4.
-Patients who are newly diagnosed and that require medication or that are undergoing treatment and require a substitution or addition of medication with an antidepressant, antipsychotic or mood stabilizer.
antidepresivo, antipsicótico o estabilizador del ánimo.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1800
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Patients who are expected no to be able to complete the study.
-Patients who are actively participating or have participated in the last three months in another clinical trial
-Patients who are pregnant or breastfeeding, or patients who intend to become pregnant in the next 12 months.
-Patients who are or require treatment with quinidine, cinacalcet and / or terbinafine (potent CYP2D6 inhibitors).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified